The Latest Breaking News from Xenon Pharmaceuticals Inc

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced new efficacy data supporting the Phase 3 development of XEN1101. XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses compared with placebo.  At Week 1, the median percent reduction in monthly focal onset seizure frequency was 55.4% in the 25 mg group, 41.5% (20…

Benzinga · Jun 23, 2022

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering

Xenon Pharmaceuticals Inc (NASDAQ:XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an additional 15% of common shares at the public offering price. Jefferies, J.P. Morgan, SVB Securities, and Stifel are acting as joint…

Benzinga · Jun 22, 2022